Fungal pleural infection due to *Microascus gracilis* with pulmonary aspergillosis after COVID-19 pneumonia

2 Zhi-Min Hu¹ | Li-Na Mao² | Ti-Ying Deng³ | Bin-Tao Su¹ | Yi Yang⁴ | Bi-Lin Dong⁵ | Qing Xu² | Shuo Yang²

- ¹ Department of Laboratory Medicine, Wuhan No.1 Hospital, Wuhan, China
- 4 ² Department of Pulmonary and Critical Care Medicine, Wuhan No.1 Hospital, Wuhan, China
- ³ Department of Pharmacy, Wuhan No.1 Hospital, Wuhan, China
- 6 ⁴ Department of Radiology, Wuhan No.1 Hospital, Wuhan, China
- ⁵ Hubei Key Laboratory for Infectious and Immune of Dermatosis, Wuhan, China
- 8 Correspondence: Shuo Yang, Department of Pulmonary and Critical Care Medicine, Wuhan No.1 Hospital, Wuhan 430022, China.
- 9 Email:244135490@qq.com
- 10

11 Abstract

- 12 Background: Scopulariopsis/Microascus is a rare but devastating pathogen due to its intrinsic resistance to nearly all available antifungal agents. Microascus gracilis, an ascomycetous mould
- 13 in the order *Microascales*, family *Microascaceae*, has recently emerged as a significant invasive pathogen causing opportunistic infections.
- 14 Objectives and Methods: We present a case of pleural infection caused by *M. gracilis* with pulmonary aspergillosis in an immunocompromised man after COVID-19 pneumonia. To further
- 15 understand the characteristics of the pathogen isolated from the patient, we identified the strain through mycological characteristics, matrix-assisted laser desorption/ionization (MALDI)
- 16 time-of-flight (TOF) mass spectrometry (MALDI-TOF MS) and internal transcribed spacer (ITS)-based sequencing, and performed *in vitro* drug susceptibility testing against common antifungal
- 17 agents. Moreover, we assessed lymphocyte subsets and programmed cell death protein 1 (PD-1) expression in peripheral blood and pleural effusion to monitor the efficacy of therapy with
- 18 thymosin- α -1 and intravenous immunoglobulin.
- 19 Results: Filamentous fungi isolated from pleural fluid were identified as *M. gracilis* based on classical morphology, mass spectrometry and molecular biology methods. The susceptibility results
- 20 in vitro revealed that multiple antifungal agents were inactive against the strain. Adjuvant immunomodulatory treatment successfully increased the levels of CD3+ T and CD4+ T cells while
- 21 decreasing the levels of CD3+PD-1+ and CD4+PD-1+ T cells in both peripheral blood and pleural effusion.
- 22 Conclusions: The immunocompromised host with opportunistic *M. gracilis* infection, rapid and accurate recognition through direct microscopic testing with calcofluor white and MOLDI-TOF
- 23 MS, is the key to achieving a definite diagnosis, and a combination of antifungal therapy with immunomodulatory therapy is vital for improving survival.
- 24
- 25 KEYWORDS
- 26 Microascus gracilis, Scopulariopsis, Microascus, Pleural effusion, COVID-19, Pneumonia
- 27

28 1 | INTRODUCTION

29

Pleural infection is a millennium-spanning condition that has been shown to be challenging to treat over many years.¹ Fungi are uncommon causes of pleural infection and 30 31 represent 3% of isolated pathogens,² but there should be a strong suspicion of underlying dormant fungal infection for differential diagnosis when episodes of pleural 32 effusions are encountered. Fungal infections tend to occur in patients with underlying immunocompromising conditions, and the most common isolated are Candida spp.³ As already well documented in medical articles, both immunocompromised and immunocompetent hosts are at an increased risk for developing fungal infections, most 33 34 commonly Candida spp. and Aspergillus spp., but other opportunistic filamentous fungi have been emerging in recent years.⁴ In particular, even though infections of the 35 genera Scopulariopsis/Microascus are very rare, as already reviewed, they are associated with high morbidity and mortality in the clinical setting due to delayed diagnosis 36 and intrinsic resistance to currently available antifungal agents.⁴ These fungi are commonly isolated from soil, air, decaying organic material, dung, insects and moist indoor environments.⁴⁻¹⁰ M. gracilis, the species of the genus Microascus, was first isolated in 1962 from food in Japan by Inagaki.¹¹ In the past, it was known as Scopulariopsis 37 gracilis, which has been recategorized and designated M. gracilis.¹⁰ Due to the increase in predisposing factors in parallel with medical technological advances, the number of 38 39 cases caused by these organisms has been on the rise.

40

41 2 | CASE REPORT

42

43 An old male presented to the hospital with cough and yellow phlegm lasting for one week followed by fever and progressive dyspnoea that developed 2 days prior to 44 admission. In December 2022, coronavirus disease 2019 (COVID-19) was diagnosed by RT-PCR for severe acute respiratory syndrome coronavirus (SARS-CoV-2) and 45 recovered with therapeutic strategies for COVID-19 pneumonia. Two month after discharge, the patient was diagnosed with nephrotic syndrome and received treatment with 46 an immunosuppressive regimen of prednisone and cyclophosphamide. The patient reported a history of hypertension for almost 10 years, and his blood pressure was 47 controlled well by using amlodipine and metoprolol. The patient's underlying conditions included chronic obstructive pulmonary disease (COPD), interstitial pneumonia, and 48 steroid-induced diabetes. On physical examination, he was revealed to be sick with wheezing and subcostal retraction requiring supplemental oxygen delivered by standard 49 nasal cannula. There was no clinical evidence of onychomycosis or paronychia. At presentation, his body temperature was 37.6 °C, his blood pressure was 142/88 mmHg. and his pulse was 92 bpm. His blood work showed an elevated leukocyte count of 13.43×10^9 cells/L, haemoglobin 137 g/L, platelets 131×10^9 /L, high sensitivity c-reactive 50 protein (hsCRP) 11.1 mg/L, erythrocyte sedimentation rate (ESR) 19 mmHg, (1,3)-beta-d-glucan (G test) 100.65 pg/mL, and IL-6 11.94 pg/mL. Serologies for the 51

52 galactomannan antigen test (GM test), syphilis, acquired immunodeficiency syndrome, and hepatitis A–E were negative. Blood and urine cultures were sterile. Chest 53 computed tomography (CT) examination showed a new right-sided pneumothorax, and ground-glass opacities (GGOs) were diffusely distributed in both lungs, especially in 54 the middle and lower lobes of the right lung (Figure 1A).

55 The timeline of diagnosis and targeted therapy is shown in Table 1. On Day 1, thoracentesis was performed, and the chest tube drainage system was maintained in an 56 upright position below the patient's chest to facilitate drainage. After that, the patient had recurrent infections in the lungs, and Acinetobacter baumannii and Aspergillus fumigatus were detected in sputum. Pulmonary symptoms were usually reduced or alleviated by empirical broad-spectrum antibiotics, including ceftriaxone/tazobactam, 57 58 levofloxacin, fluconazole (FLZ) and voriconazole (VRC), for approximately 3 weeks. On Day 32, Enterococcus faecalis was incubated in the pleural fluid, and 59 anti-biotherapy was adjusted to vancomycin for 3 weeks. The signs and symptoms of spontaneous hydropneumothorax were improved. On Day 65, the pathogen causing 60 pleural reinfection was Streptococcus sanguinis, and the therapeutic agent was switched to ceftriaxone/tazobactam for 2 weeks. On Day 73, the symptoms of pneumonia and 61 empyema were alleviated, and he was discharged home with intercostal drainage (ICD) in situ. Eight days later, he was readmitted because of worsening of dyspnoea, cough and wheezing, and no fever. According to the patient's recollection, the chest drain was unsecure for fixation and accidental removal in house. His blood work showed a low 62 63 absolute lymphocyte count 320/L. Abnormal laboratory findings included elevated hsCRP 189.3 mg/L and peripheral blood cytomegalovirus 1070 copies/ml. Repeated CT 64 revealed a drainage tube, a cavity with an air-crescent sign and reduced hydropneumothorax in the right pleural cavity (Figure 1B). Klebsiella pneumoniae was detected in 65 sputum, and anti-biotherapy was switched to latamoxef and valganciclovir for two weeks. After unplanned extubation, the new pleural catheter was reintubated away from the original region (Figures 2A). The culture from the removed chest tube was positive for mould growth. From Day 89 to Day 93, multiple cultures of pleural fluid from the 66 new tube were positive for the same mould. Calcofluor white staining revealed many pigmented, septate fungal hyphae (Figures 2B) of the pleural fluid and septate fungal 67 hyphae of BALF. In addition, the sample was separately inoculated onto Sabouraud's dextrose agar (SDA) at 35 °C. The T-spot test and MTB/RIF GeneXpert detection 68 69 assays were negative. Both G and GM tests were negative in serum and pleural fluid. However, the antifungal strategy of caspofungin (CAS, 50 mg/day) and posaconazole (POS, 0.3 g/day) was initiated despite the discouraging result of *in vitro* susceptibilities, and improvement of pleural effusion was achieved after 5 weeks of treatment. No 70 71 adverse events were reported. On Day 95, intermittent fever was observed after the administration of the combined antifungal therapy. The serum and pleural fluid GM tests 72 were still negative, and blood cultures were all sterile. A quantitative real-time PCR assay was developed to measure the human cytomegalovirus (HCMV) DNA load in 73 peripheral blood, which was 2589 copies/ml. The BALF collected for metagenomics next generation sequencing (mNGS) showed high sequence numbers and relative abundance of Pneumocystis jirovecii, Aspergillus fumigatus, HCMV and EBV. The BALF GM antigen test was positive. With regard to the patient's immunological and 74 75 infectious condition, clindamycin 1.2 g/day, thymosin-a-1 4.8 mg/week and intravenous immunoglobulin 400 mg/kg/week were added. On Day 119, the symptoms of the ⁷⁶ lungs and pleural infection were relieved, the chest tube was removed, and the culture of the pleural catheter, pleural effusion and sputum were all negative. On Day 146, the ⁷⁷ nucleic acid of cytomegalovirus was normal, and the high level of CRP and persistent low level of absolute lymphocyte count were relieved. A chest CT scan showed that ⁷⁸ bilateral lung infection and pneumothorax were partly absorbed, lung tissue compression was less than 3%, and pleural effusion was reduced. The patient was discharged with ⁷⁹ no chief complaints and switched to terbinafine (TEB) 250 mg/day combined with POS 0.3 g/day for 4 weeks. After 3 months of follow-up, the patient had no obvious ⁸⁰ discomfort.

81

82 **3 | MATERIALS AND METHODS**

83 The authors confirm that the ethical policies of the journal, as noted on the journal's author guidelines page, have been adhered to and that appropriate ethical review
84 committee approval has been received.

85

86 **3.1** | Fungal pathogen identification

87 Microbiological tests were implemented with pleural fluid, puncture drainage tubes and bronchoalveolar lavage fluid (BALF). The isolates obtained were identified by 88 examination of micromorphological and macromorphological characteristics. After pretreatment with 70% formic acid and a-cyano-4-hydroxycinnamic acid (HCCA, Sigma-Aldrich). The strains were identified by matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) mass spectrometry (MALDI-TOF MS, Zybio 89 EXQ2000, Zhongyuan Huiji Biotechnology Co. Ltd.) according to the standard operation protocol.¹² Mycelia were mechanically disrupted by liquid nitrogen grinding, 90 followed by genomic DNA extraction using QIAGEN's DNeasy® Plant Kit.¹³ The internal transcribed spacer region (ITS) was amplified with the primer pair ITS1 91 92 (5'-TCCGTAGGTGAACCTGCGG-3') and ITS4 (5'-TCCTCCGCTTATTGATATGC-3'). DNA sequences were analysed using NCBI BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi). 93

94

95 3.2 | Antifungal susceptibility testing

 $1n \ vitro$ susceptibility was tested according to the guidelines presented in document M38-A₂ of the Clinical and Laboratory Standards Institute (CLSI).¹⁴ The minimum inhibitory concentration (MIC) was determined visually as the concentration that resulted in 100% inhibition. The minimal effective concentration (MEC) endpoint was taken

98 as the lowest concentration at which the visual growth pattern change from granular to filamentous growth was detected, microscopically seen as restricted hyphal

99 growth.^{14,15}

100

101 **3.3** | Flow cytometry analysis

102 To monitor lymphocyte subsets and programmed cell death protein 1 (PD-1) expression in peripheral blood and pleural effusion to evaluate the efficacy of therapy with 103 thymosin- α -1 and intravenous immunoglobulin, simultaneous identification and enumeration of T lymphocytes in whole blood and multicolour flow cytometric analysis of 104 lymphocyte subsets as well as CD4+ and CD8+ T-cell subset ratios were determined using an automated AQUIOS cytometer (Beckman Coulter), as per the manufacturer's 105 instructions for use. Each site had an instrument and all needed reagents. Ten millilitres of pleural fluid was passed through a 40 μ m filter, and the cellular pellet was spun 106 down. Then, red blood cells (RBCs) were lysed using a soft RBC lysing solution (Beckman Coulter). Cellular viability was then assessed using fluorescent reactive dye.¹⁶

107

108 **3.4** | Literature review

We performed a literature search of *Scopulariopsis* or *Microascus* pleural infection and *Scopulariopsis gracilis* or *Microascus gracilis* infection published from 1962 to 2023 via the PubMed database (https://pubmed.ncbi.nlm.nih.gov/). In addition, the references cited in these reports have been reviewed to identify additional cases that were not found in the PubMed database. The review included an assessment of all demographic features, including year/nation, age/gender, underlying disease, transplant type, systemic antifungal agents before infection, involved sites, identified fungal organisms, treatment and therapeutic outcomes. Only those cases that met the criteria for "proven invasive fungal disease" caused by moulds as described by the consensus group of the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) were included in this evaluation.¹⁷

115

116 4 | **RESULTS**

117 4.1 *M. gracilis* and *A. fumigatus* were identified according to classical morphology, mass spectrometry and molecular biology methods.

Colonies grown on SDA were first visible on Day 2 of incubation and developed into small mould colonies over the next few days (Figure 2C). The colonies were initially pale but developed a velvety and olivaceous grey colour after 2 weeks. Lacto-phenol cotton blue mounts of the colonies showed conidiophores mostly irregularly branched, usually consisting of clusters of 2 to 3 annellides borne on short branches. Annellides lageniform or somewhat cylindrical with a slightly swollen base. Conidia subspherical to ellipsoidal, with truncate base and rounded or pointed aped, arranged in long chains (Figure 2D). *M. gracilis* and *A. fumigatus* were identified by mycological 122 characteristics, MALDI-TOF MS (Figure 2E) and ITS-based sequencing (accession no. OR131328).

123

124 4.2 M. gracilis manifests as a multidrug-resistant strain

The results revealed that multiple antifungal agents were inactive against *M. gracilis*, with MIC values of 4 µg/ml for amphotericin B (AMB), 8 µg/ml for VRC, > 8 µg/ml for POS, >16 µg/ml for itraconazole (ITC), >64 µg/ml for 5-flucytosine (5-FC), >256 µg/ml for FLZ, and minimal effective concentration (MEC) values all > 8 µg/ml for echinocandins. The susceptibility profiles of *A. fumigatus* showed POS 0.06 µg/ml, ITC 0.12 µg/ml, VRC 1 µg/ml, AmB 4 µg/ml, 5-FC >64 µg/ml and echinocandins all 8 µg/ml.

129

4.3 Adjuvant immunomodulatory treatment successfully increased the levels of CD3+ T and CD4+ T cells while decreasing the levels of CD3+PD-1+ T and
 CD4+PD-1+ T cells

The inflammatory indicators, lymphocyte subsets and PD-1 expression in peripheral blood and pleural effusion were evaluated before and after adjuvant immunomodulatory treatment with thymosin- α -1 and intravenous immunoglobulin. The levels of CD3+ T cells and CD4+ T cells were alleviated (Figure 3), while CD3+PD-1+ T cells and CD4+PD-1+ T cells were all decreased significantly both in blood (Figure 4) and pleural effusion (Figure 5) after the immunomodulatory agents were administered. Other abnormal biochemical biomarkers, such as hsCRP and IL-6 in peripheral blood and LDH, ADA, IL-1 β and IL-6 in pleural diffusion, all declined substantially. (Table 2)

136

137 **4.4 Literature review**

A review of the English literature since 1962 identified 5 cases reported as proven pleural *Scopulariopsis/Microascus* infections.¹⁸⁻²² The reported cases listed in Table 3 had a median age of 52.8 years (range 27-70 years) and represented 6 males. Of these cases, 2 were from the USA, and 1 each was from Belgium, India, France and China. Of these patients, 80% had solid organ transplant (SOT), and all were associated with lung transplantation. Sixty percent of patients were treated with azole antifungal prophylaxis. Because of the isolate morphologically identified as *M.cinereus* was found after sequencing to be from *M. gracilis*.^{4,10} The most commonly identified species was *M. gracilis* (3/6, 50%), followed by *S. brumptii* (2/6, 33.3%) and *S. acremonium* (1/6, 16.7%). Combined therapies were performed when diagnostic clues were found, but the therapeutic outcomes were worse, as 83.3% of patients died.

144 To date, only six proven cases of *M. gracilis* infections have been reported, including two cases of disseminated infection,^{20,22} two cases of invasive bronchopulmonary

infection, 23,24 and each case of primary subcutaneous infection²⁵ and keratitis. 26 A total of 83.3% of cases were underlying diseases that compromised the immune system locally or systemically. A total of 66.7% of patients also received azole antifungal prophylaxis. In addition, 66.7% were cured successfully, while the salvage treatment for two disseminated patients failed.

148

149 5 | DISCUSSION

150 M. gracilis, the teleomorph of Scopulariopsis/Microascus spp., is a rare opportunistic fungus associated with human disease and is commonly found in soil, decaying organic matter and in-house environments.^{4,7,8,10,22-26} There is a paucity of information available concerning clinical infections caused by *M. gracilis*. Among the ninety-seven clinical 151 152 strains morphologically identified as Scopulariopsis/Microascus spp., M. gracilis was the second most commonly isolated species and was most frequently isolated from 153 BALF and sputum samples.⁸ Most of them, according to the clinical features, were determined to have fungal colonization.⁸ The diagnosis of *Scopulariopsis/Microascus* infections is challenging because of the delay in microbiological study completion.⁴ Precise and timely identification of these pathogens to species can be extremely 154 155 important when recovered from high-risk patients. However, morphological conclusion requires sporulating culture, which considerably delays the diagnosis, while the 156 developed DNA-based assays for identification are rapid and reliable.²⁷ Typically, the isolate morphologically identified as *M.cinereus* was found after sequencing to be from *M. gracilis.*²⁰ Our strain accurately identified by morphological features, mass spectrometry and ITS-based sequencing is the seventh invasive *M. gracilis* infection, as well as 157 158 the sixth pleural infection caused by Scopulariopsis/Microascus spp.. Notably, in comparison to DNA-based assays, mass spectrometry analysis based on the updated database offers a cost/time-saving and accurate clinical working protocol for identifying both the genus and species levels of the Scopulariopsis/Microascus genera. 159

160 The development of spontaneous hydropneumothorax is a complication of post-COVID-19 pneumonia due to rupture of the small airway.²⁸ A history of recent COVID-19 161 infection is a risk factor for pleuropulmonary infections, particularly in patients with comorbidities, structural defects such as bronchopleural fistula, and immunosuppressive therapies.²⁹ The presence of *M. gracilis* may represent colonization or may cause localized infections at the usual residential location of the superficial tissue or the lungs.^{22,30} 162 163 As the most representative aetiologic agent in Scopulariopsis/Microascus spp. infection of the pleura in extremely limitated data, M. gracilis occurs less frequently but causes 164 refractory and fatal disseminated infections. Opportunistic infections of this extremely rare fungus have been reported mostly in immunocompromised patients, with most severe infections occurring in solid organ transplant patients, particularly lung transplant patients.^{18,20-24} We suspected that treatment with corticosteroids for nephrotic 165 syndrome might have transiently suppressed immunity, resulting in opportunistic infection. Prognosis is poor, and mortality is high in immunosuppressed patients.^{8,31} 166 167 Furthermore, it is worth mentioning that more than 60% of patients acquired the infection when they were under antifungal prophylaxis with azole agents. The selective 168 pressure of antifungal prophylaxis may also contribute to the appearance of rarely invasive fungal infections, caused by moulds that are often intrinsically resistant to some

classes of antifungals, which have been described as opportunistic pathogens in patients with a variety of underlying diseases.³²⁻³⁴ Pneumocvstis pneumonia most often occurs 169 170 in immunocompromised hosts, with intensified or prolonged immunosuppression, notably with corticosteroids and subsequent cytomegalovirus (CMV) infections.³⁵ Coinfection with CMV may contribute to further immune dysregulation in haematopoietic cell transplant (HCT) and solid organ transplant (SOT) recipients.³⁶ A total of 171 42.9% of SOT patients had a proven CMV infection that occurred in concurrent infection with Scopulariopsis/Microascus spp., 18,23,37,38 possibly because CMV can affect 172 173 several components of the defence system and, therefore, could enhance the pathogenicity of other infectious agents.^{18,23,39} It is worth noting that our patient experienced a 174 persistent low absolute lymphocyte count. Based on the analysis of lymphocyte subsets in peripheral blood and pleural effusion through flow cytometry assays, the number of T lymphocytes was significantly decreased, and T-cell exhaustion occurred. The host cannot control infections effectively because of T-cell exhaustion.⁴⁰ PD-1 together with 175 176 programmed death-ligand 1 (PD-L1) is a key biomarker of lymphocyte depletion,⁴¹ and upregulation of PD-1 in exhausted T cells as an immunosuppressive receptor was observed during the progression of symptomatic stages of infections, which contributes to the evolution of the severe form of the symptoms. Prognosis largely depends on the 177 178 immune status of the patient, and immune reconstitution is considered essential when combating invasive fungal infections.⁸ In conclusion, elevated PD-1 levels in CD4+ T 179 cells were associated with the inhibition of cell proliferation and decreased effector functions;⁴² in contrast, blocking or downregulating PD-1 reversed exhausted T cells, and 180 immunosuppressive status resulted in recovery and enhancement of host innate immunity.

The potential origin of infection is vastly diverse. Outbreaks of fungal keratitis and invasive disease due to contaminated grafts used to store the issued corneoscleral 181 button,²⁶ soil contamination^{43,44} or inhaled pollution,⁴⁵, respectively, have been described in immunocompetent hosts. In addition to the severe immunocompromised host 182 183 susceptible to invasion of the opportunistic Scopulariopsis/Microascus, especially in those patients who had undergone solid organ transplants, transmission of the fungus from the donor was possible,^{4,21} and the fungus might have been accessed into the pleural space during prehospital placement of thoracostomy tubes²¹ or introduced into the 184 skin and then into the vessels through trauma at a catheter site.⁴⁶ Our patient was another case of catheter-related pleural infection contaminated by the indoor environment. 185 To minimize the fungal equivalent and avoid persistent infection, the contaminated catheter should be removed immediately. The delayed diagnosis and the high rates of 186 resistance of Scopulariopsis/Microascus to practically all current antifungals ^{8,31,47,48} are responsible for the high mortality associated with disseminated infections.^{18,20,21,22} A 187 188 spread of pulmonary Scopulariopsis/Microascus to the pleura is unlikely in the present case because only pleuritis was detected without apparent pulmonary Scopulariopsis/Microascus. 189

190 Currently, fungal empyema therapy is not protocolized, and combinations that include available agents can be used due to the variable penetration of systemically 191 administered antifungals into the pleural cavity.⁴⁹ First-line treatment for systemic fungal infections, AMB and VRC, and other antifungal agents are ineffective against 192 *Scopulariopsis/Microascus* spp. *in vitro*. The lack of correlation between *in vitro* and *in vivo* studies and the intrinsic resistance of fungal pathogens to many of the available

antifungals limits successful therapeutic options.⁵⁰ Susceptibility testing using CLSI or EUCAST methodologies usually shows high MIC values for all currently approved 193 antifungal agents.^{8,47} No cut-off values have been determined, as there are insufficient data to correlate MIC values and clinical outcomes.⁵¹ Nevertheless, *in vitro* synergy has 194 been demonstrated with combinations of POS and TEB, POS and caspofungin (CAS), AMB and CAS, and three drugs in combination.^{30,52} L-AMB (3–10 mg/kg/day) and 195 VRC,^{52,53} VRC alone (i.v. and then oral step-down therapy), and lipid formulations of AMB with other antifungal agents can be moderately recommended.⁵² VRC with an 196 echinocandin and TEB is marginally recommended.^{20,52} Limited literature on *M. gracilis* indicates higher MICs in vitro, ^{20,22,23,25,30,48} approximately 85.7% of the isolates had 197 high concentrations for AmB, CAS, VOR and POS, except one case had relatively low concentrations for AMB,²² CAS,⁴⁸ VOR and POS,²³ respectively. All strains had high 198 MIC values for FLZ, ITC, and 5-FC. The MEC values of micafungin were 0.25^{23} and 1 µg/ml,²² and the MIC of isavuconazole was established at 2 µg/ml.^{22,54} It is worth 199 200 mentioning that the value of TEB fluctuated obviously from 1 to 16 µg/ml. The fractional inhibitory concentration indices (FICIs) range of CAS, POS, and TRB combination against *M. gracilis* was from 0.321 to 0.320, which appear to be promising, with a synergistic effect on *M. gracilis*³⁰ The MIC, POS, and TRB combination in invasive 201 202 infections warranted to be an effective therapy in clinical practice.^{23,24} The other therapeutic strategies include nebulized micafungin for the treatment of Scopulariopsis/Microascus tracheobronchitis,⁵⁵ combination of treatment for Scopulariopsis/Microascus pneumonia, which included surgery, triple combination of antifungal 203 drugs, and granulocyte-colony stimulating factor.⁵⁶ Moreover, an investigational antifungal within the orotomide class that is currently in late-stage clinical development, 204 205 olorofim (formerly F901318), demonstrated good in vitro activity against the majority of Scopulariopsis/Microascus isolates tested, with an MIC90 value of 0.125 mg/L and a 206 modal MIC of 0.03 mg/L.⁵⁷ Surgical debridement (where feasible) and reversal of the host's innate immunodeficiency are critical to survival and are strongly recommended.⁵² 207 Particularly, for immunocompromised patients, intravenous immunoglobulin was essential to reverse the immunological crisis and was obtained with highly effective clinical 208 outcomes.²³ Although there is limited information about thymosin $\alpha 1$ (T $\alpha 1$) as adjuvant immunomodulatory therapy, either used alone or combined with other treatments, the 209 favourable combination of $T\alpha 1$ with an anti-PD-1 antibody has already been postulated experimentally. $T\alpha 1$ may be a treatment option for invasive fungal infection in 210 immunocompromised hosts, but efficacy and safety data remain limited. Our immunocompetent patient was initially treated with CAS combined with POS; when the 211 symptoms and critical biological index were relieved, the POS and TRB combination started as a sequential therapy until he was cured. Moreover, a combination of 212 antifungal therapy with immunomodulatory therapy was shown to be an effective intervention.

In summary, the patient's underlying comorbidities, history of recent COVID-19 infection, immunosuppressive therapy, antifungal prophylaxis with azole drugs, cytomegaloviremia, lymphocyte depletion and indwelling catheter may have played a role in the pleural seeding of *M. gracilis*. Fortunately, our patient was beneficial for successful management in a multimodal manner, including reversal or revocation of underlying predisposing factors, early administration of suitable antifungal agents, and adjuvant immunomodulatory treatment in which his condition did not progress into disseminated *Scopulariopsis/Microascus*. Although infection with *M. gracilis* is uncommon and rarely pathogenic in the pleural cavity, clinicians and microbiologists should be aware of the potential of *M. gracilis* infection in immunocompromised individuals at risk of opportunistic infections. Early and definitive diagnosis thorough direct microscopic testing with calcofluor white, as well as MOLDI-TOF MS, which

219 has been suggested as a valuable tool for identification at the genus and the species level, is the key to rapidly recognize this rare pathogenic fungus. Achieving an accurate

- 220 diagnosis along with appropriate antifungal management is vital for improving survival.
- 221

222 AUTHOR CONTRIBUTIONS

223 Zhi-Min Hu: Investigation; methodology; formal analysis; writing-review and editing; writing – original draft; resources; visualization; data curation. Li-Na Mao: collected 224 and interpreted the clinical data and wrote the manuscript. Ti-Ying Deng: Investigation; formal analysis; resources. Bin-Tao Su: revised the manuscript critically for 225 important content. Yi Yang: carried out the radiological examination. Bi-Lin Dong: carried out the microbiological examination and nucleotide sequencing. Qing Xu: 226 Investigation; formal analysis. Shuo Yang: Methodology; supervision; project administration; writing – review and editing. All the authors have read and approved the final 227 manuscript.

228

229 ACKNOWLEDGEMENTS

230 This work was supported by the Wuhan Health Scientifc Research Key Project (No.WX18A06), and the Wuhan Health Scientifc Research Program(No.WH21C21).

231

232 CONFLICT OF INTEREST STATEMENT

233 No potential conflict of interest was reported by the authors.

234

235 **REFERENCES**

- 1. Sundaralingam A, Banka R, Rahman NM. Management of pleural infection. Pulm Ther. 2021;7(1):59-74.
- 237 2. Hassan M, Cargill T, Harriss E, et al. The microbiology of pleural infection in adults: a systematic review. Eur Respir J. 2019;54(3):1900542.
- 238 3. Hassan M, Patel S, Sadaka AS, et al. Recent insights into the management of pleural infection. Int J Gen Med. 2021;14:3415-3429.

- 4. Pérez-Cantero A, Guarro J. Current knowledge on the etiology and epidemiology of Scopulariopsis infections. Med Mycol. 2020;58(2):145-155.
- 5. Barron GL, Cain RF, Gilman JC. The genus *Microascus. Can.J.Botany.* 1961;39:1609–1631.
- Samson RA, Houbraken J, Thrane U, Frisvad JC, Andersen B. Food and Indoor Fungi. Westerdijk Laboratory Manual series: 2, second edition. 2 ed. Utre
 cht: Westerdijk Fungal Biodiversity Institute. 2019;481 p. (Westerdijk Laboratory Manual series).
- Woudenberg JHC, Meijer M, Houbraken J, Samson RA. *Scopulariopsis* and *scopulariopsis*-like species from indoor environments. *Stud Mycol.* 2017;88:1-35.
- Sandoval-Denis M, Sutton DA, Fothergill AW, et al. *Scopulariopsis*, a poorly known opportunistic fungus: spectrum of species in clinical samples and in v
 itro responses to antifungal drugs. *J Clin Microbiol*. 2013;51(12):3937-3943.
- 9. Iwen PC, Schutte SD, Florescu DF, Noel-Hurst RK, Sigler L. Invasive *Scopulariopsis brevicaulis* infection in an immunocompromised patient and review o
 f prior cases caused by *Scopulariopsis* and *Microascus* species. *Med Mycol.* 2012;50(6):561-569.
- 249 10. Sandoval-Denis M, Gené J, Sutton DA, et al. Redefining microascus, Scopulariopsis and allied genera. Persoonia. 2016;36:1-36,
- 250 11. Inagaki N. On some fungi isolated from foods (I). Trans Mycol Soc Japan. 1962;4(1):1-5.
- Wei L, Shao J, Song Y, et al. Performance of matrix-assisted laser desorption Ionization-time of flight mass spectrometry for identification of *Scedosporium*,
 Acremonium-like, *Scopulariopsis*, and *Microascus* specie. *Front Microbiol*. 2022;13:841286.
- 13. Bellemare A, John T, Marqueteau S. Fungal genomic DNA extraction methods for rapid genotyping and genome sequencing. *Methods Mol Biol.* 2018;1775:
 11-20.
- Rex JH, Alexander BD, Andes D, et al. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi, Approved Standard. 2
 nd ed. M38-A2 National Committee for Clinical Laboratory Standards; 2008.
- 15. Clinical and Laboratory Standards Institute. Performance Standards for Antifungal Susceptibility Testing of Filamentous Fungi. 2nd ed. CLSI supplement M6
 1. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.
- 16. Juan C. Nieto, Carlos Zamora, José M. Porcel, et al. Migrated T lymphocytes into malignant pleural effusions: an indicator of good prognosis in lung ade
 nocarcinoma patients. Sci Rep. 2019;9:2996.
- 17. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of C
 ancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Con

263 sensus Group. *Clin Infect Dis.* 2008;46:1813-1821.

- 18. Wuyts WA, Molzahn H, Maertens J et al. Fatal *Scopulariopsis* infection in a lung transplant recipient: a case report. *J Heart Lung Transplant*. 2005;24:230
 1–2304.
- Shankar EM, Vignesh R, Barton RC, et al. Hydrothorax in association with *Scopulariopsis brumptii* in an AIDS patient in Chennai, India. *Trans R Soc Tr op Med Hyg.* 2007;101(12):1270-1272. doi:10.1016/j.trstmh.2007.09.008.
- 268 20. Miossee C, Morio F, Lepoivre T et al. Fatal invasive infection with fungemia due to *Microascus cirrosus* after heart and lung transplantation in a patient
 269 with cystic fibrosis. J Clin Microbiol. 2011;49:2743–2747.
- 21. Shaver CM, Castilho JL, Cohen DN, et al. Fatal *Scopulariopsis* infection in a lung transplant recipient: lessons of organ procurement. *Am J Transplant*. 20
 14;14:2893–2897.
- 272 22. Ding Y, Steed LL, Batalis N. First reported case of disseminated Microascus gracilis infection in a lung transplant patient. IDCases. 2020; 22:e00984.
- 273 23. Huang L, Chen W, Guo L, et al. *Scopulariopsis/Microascus* isolation in lung transplant recipients: a report of three cases and a review of the literature. *M* 274 *ycoses*. 2019;62(10):883-892.
- 24. Gao B, Guo L, Zhao L, et al. Case Report of a Successfully Treated *Scopulariopsis* Infection in a Bilateral Lung Transplant Recipient. *Exp Clin Transpla nt.* 2023;21(3):275-278.
- 277 25. Mhmoud NA, Siddig EE, Nyuykonge B, Bakhiet SM, van de Sande WWJ, Fahal AH. Mycetoma caused by *Microascus gracilis*: a novel agent of human
 278 eumycetoma in Sudan. *Trans R Soc Trop Med Hyg.* 2021;115:426–430.
- 26. Wilde C, Messina M, Moshiri T, Snape SE, Maharajan S. Interface *Scopulariopsis gracilis* fungal keratitis following Descemet's stripping automated endoth elial keratoplasty (DSAEK) with a contaminated graft. *Int Ophthalmol.* 2018;38(5):2211-2217.
- 27. Kordalewska M, Jagielski T, Brillowska-Dąbrowska A. Rapid assays for specific detection of fungi of *Scopulariopsis* and *Microascus* genera and *Scopulario* psis brevicaulis species. *Mycopathologia*. 2016;181(7-8):465-74.
- 28. Kumar R, Mishra N. Lung decortication for spontaneous hydropneumothorax in post COVID patients: A case series. *Perioper Care Oper Room Manag.* 20
 28. 22;29:100279.
- 285 29. Patel VM, Patel SV, Singletary K, Pacheco L. Recurrent hydropneumothorax after COVID-19. Cureus. 2023;15(3):e36208.
- 286 30. Yao L, Wan Z, Li R, Yu J. In vitro triple combination of antifungal drugs against clinical Scopulariopsis and Microascus species. Antimicrob Agents Chem

- *other*. 2015;59:5040–5043.
- Paredes K, Capilla J, Mayayo E, Guarro J. Virulence and resistance to antifungal therapies of *Scopulariopsis* species. *Antimicrob Agents Chemother*. 2016;6
 0(4):2063-2068.
- 290 32. Lamoth F, Chung SJ, Damonti L, Alexander BD. Changing epidemiology of invasive mold infections in patients receiving azole prophylaxis. *Clin Infect Di* 291 s. 2017;64:1619–1621.
- 33. Jenks J, Reed SL, Seidel D, et al. Rare mold infections caused by *Mucorales, Lomentospora prolificans* and *Fusarium*, San Diego: the role of antifungal c
 ombination therapy. *Int J Antimicrob Agents*. 2018;52:706-712.
- 34. Stemler J, Salmanton García J, Seidel D, et al. Risk factors and mortality in invasive *Rasamsonia spp.* infection: analysis of cases in the FungiScope(R)
 registry and from the literature. *Mycoses.* 2020;63:265-274.
- 35. Apostolopoulou A, Fishman JA. The pathogenesis and diagnosis of *Pneumocystis jiroveci* pneumonia. *J Fungi (Basel)*. 2022;8(11):1167.doi:10.3390/jof811116
 7.
- 36. Gea-Banacloche, J.,Komanduri, K., Carpenter, P., et al. National institutes of health hematopoietic cell transplantation late effects initiative: the immune dysr
 egulation and pathobiology working group report. *Biol Blood Marrow Transplant*. 2017;23(6),870–881.
- 300 37. Swick BL, Reddy SC, Friedrichs A, Stone MS. Disseminated *Scopulariopsis*-culture is required to distinguish from other disseminated mould infections. J
 301 *Cutan Pathol.* 2010;37(6):687-691.
- 302 38. Helander L, Stark M. Fatal Scopulariopsis brumptii in a pediatric immunocompromised host. Fetal Pediatr Pathol. 2017;36(1):82-86.doi:10.1080/15513815.2
 303 016.1267283.
- 304 39. Singh N. Interactions between viruses in transplant recipients. Clin Infect Dis. 2005;40(3):430-436.
- 305 40. E. J. Wherry. T cell exhaustion. *Nature Immunology*. 2011;12(12):492-499.
- 306 41. Sakuishi K, Apetoh L, Sullivan JM, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. *J Exp Med.* 307 2010;207(10):2187-2194.
- 42. Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533-535.
- 309 43. Sellami A, Boudaya S, Makni F, et al. Disseminated infection by Scopulariopsis brevicaulis. J Mycol Med. 2003;13:203-206.
- 44. Chen-Scarabelli C, Scarabelli TM. Fungal Endocarditis due to Scopulariopsis. Ann Intern Med. 2003;139(9):W77.doi:10.7326/0003-4819-139-9-200311040-000

311 22-w1.

- 45. Celard M, Dannaoui E, Piens MA, et al. Early *Microascus cinereus* endocarditis of a prosthetic valve implanted after Staphylococcus aureus endcarditis of
 the native valve. *Clin Infect Dis.* 1999;29:691–692.
- 46. Steinbach WJ, Schell WA, Miller JL, Perfect JR, Martin PL. *Scopulariopsis brevicaulis* infection in a perdiatric stem-cell transplant patient treated with vor iconazole and caspofungin and a review of *Scopulariopsis* infections in immunocmpromised patients. *J Infect*. 2004;48:112–116.
- 316 47. Aguilar C, Pujol I, Guarro J. In vitro antifungal susceptibilities of Scopulariopsis isolates. Antimicrob Agents Chemother. 1999;43:1520–1522.
- 48. Skóra M, Bulanda M, Jagielski T. In vitro activities of a wide panel of antifungal drugs against various *Scopulariopsis* and *Microascus* species. *Antimicrob* 318 Agents Chemother. 2015;59:5827–5829.
- 49. Matsuda T, Koreeda Y, Mataki H, et al. A case of *Aspergillus* empyema successfully treated with combination therapy of voriconazole and micafungin: exc
 ellent penetration of voriconazole and micafungin into pleural fluid. *Intern Med.* 2010;49(12):1163-1169
- Salmanton-García J, Koehler P, Kindo A, et al. Needles in a haystack: extremely rare invasive fungal infections reported in FungiScope®-global registry fo
 r emerging fungal infections. J Infect. 2020;81:802–815.
- 51. Cuenca-Estrella M, Gomez-Lopez A, Buitrago MJ, et al. In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen *Scop ulariopsis brevicaulis*. Antimicrob Agents Chemother 2006;50:2248–2250.
- 325 52. Bupha-Intr O, Butters C, Reynolds G, et al. Consensus guidelines for the diagnosis and management of invasive fungal disease due to moulds other than
 326 Aspergillus in the haematology/oncology setting, 2021. Intern Med J. 2021;51(Suppl 7):177-219.
- 53. Kurata K, Nishimura S, Ichikawa H, Sakai R, Mizutani Y, Takenaka K, et al. Invasive *Scopulariopsis alboflavescens* infection in patient with acute myeloi
 d leukemia. *Int J Hematol* 2018;108:658-664.
- 54. Arroyo MA, Walls TB, Relich RF, Davis TE, Schmitt BH. The brief case: *Scopulariopsis* endocarditis-a case of mistaken Takayasu's arteritis. *J Clin Micro biol.* 2017;55:2567-2572.
- 55. Los-Arcos I, Berastegui C, Martín-Gómez MT, et al. Nebulized micafungin treatment for *Scopulariopsis/Microascus* tracheobronchitis in lung transplant reci
 pients. *Antimicrob Agents Chemother*. 2021;65(6):e02174-20.
- 56. Ustun C, Huls G, Stewart M, Marr KA. Resistant *Microascus cirrosus* pneumonia can be treated with a combination of surgery, multiple anti-fungal agents
 and a growth factor. *Mycopathologia*. 2006,162(4):299-302.

57. Wiederhold NP, Patterson HP, Sanders CJ, Cañete-Gibas C. Dihydroorotate dehydrogenase inhibitor olorofim has potent in vitro activity against Microascus/ Scopulariopsis, Rasamsonia, Penicillium and Talaromyces species. Mycoses. 2023;66(3):242-248. FIGURE 1 Chest computed tomography showed a new pneumothorax on the right lung, and ground-glass opacities were diffusely distributed in both lungs (A); a drainage tube, a cavity with an air-crescent sign and reduced hydropneumothorax in the right pleural cavity (B) FIGURE 2 The image showed the new intercostal catheter on the right-sided chest(A). Calcofluor white staining showed the pigmented, septate fungal hyphae of pleural effusion, ×400 (B). The picture displays Microascus gracilis on Sabouraud's dextrose agar after 5 days of incubation at 35 °C (C). Microscopic examination showing hyaline septate hyphae with bottle-shaped conidiogenous cells along with obovate-shaped, smooth conidia arranged in short chains, lactophenol cotton-blue staining, ×400 (D). The characteristic spectrometry of *M. gracilis* identified by MOLDI-TOF MS (E). FIGURE3 Flow cytometry results displayed the level of CD3+ T cells and CD4+ T cells were alleviated in peripheral blood after the immunomodulatory agents administered. FIGURE4 Flow cytometry results reveals the level of CD3+PD-1+ T cells and CD4+PD-1+ T cells were all decreased significantly in peripheral blood after the immunomodulatory agents administered. FIGURE 5 Flow cytometry results reveals the level of CD3+PD-1+ T cells and CD4+PD-1+ T cells were all decreased significantly in pleural effusion after the immunomodulatory agents administered.









	2984.567	1253	359408	3	466
	3043.404	1265	286418	2	532
8	3095.842	2115	1481954	12	590
Ê.	3300,269	1768	1179633	8	478
	3353.365	1755	1598522	7	646
	3369,651	6568	8817295	62	523
	3385.164	2278	2501588	13	359
r.	3407.045	1717	1227045	7	478
r.	3595.101	1401	579368	4	475
0	3674.655	1403	753917	4	665
1	3689.662	2149	2049925	12	662
2	3846.615	1465	837907	5	598
3	3860.224	1645	1253200	7	6.7
4	4079.175	1523	950247	6	600
5	4' 18.782	1449	934189	5	550
6	4 62.947	1170	429129	2	41
7	4464.275	1462	917926	5	457
8	4967.589	1447	1053664	5	720
ł					105
	Microascus	9.51	0 ***		
1	Microascus	5.88	2 ★		
	Microascus	5.61	7 ★		
	Pen cillium o	5.51	5 ★		
	Scedosporiu	5,47	0 ★		
;	Aspergillus r	5.29	6 ★		
	Scedosporiu	5.20	6 ★		
1	Scedosporiu	im apiosp	ermum	5.16	4 ★
	Aspergillus t	5.00	2 ★		
	the second se	and a second			the second s







TABLE 1 Timeline of events

Time	Clinical features	Biology results	Therapy strategies			
D1	Progressive dyspnoea	Neutrophilia, abnormal chest CT scan	Chest tube insertion			
D6	Fever	Acinetobacter baumannii detected in sputum, High level of	Cefoperazone-sulbactam 9 g/day IV and prophylactic			
		CRP, SAA, IL-6 and (1,3)-beta-d-glucan, low absolute	therapy fluconazole 0.2 g/day p.o.			
		lymphocyte count				
D10	Pneumonia and cough	Aspergillus fumigate detected twice in sputum	Levofloxacin 0.4 g/day and cefoperazone-sulbactam 9 g/day IV combined antifungal therapy (voriconazole 0.4			
			g/day p.o.)			
D32	Pleurisy	Enterococcus faecalis detected in pleural fluid, High level of	Switched to vancomycin 2 g/day IV			
		CRP and IL-6, low absolute lymphocyte count				
D65	Increased pleural effusions	Streptococcus sanguinis detected in pleural fluid	Adjusted to cefoperazone-sulbactam 9 g/day IV			
D73	Outpatient	Negative sputum and pleural fluid				
D81	Readmitted due to worsening of the dyspnoea	High level of CRP and glycaemia, abnormal chest CT scan				
D87	Extubation and indwelling a new pleural catheter, cough	Cytomegaloviremia and persistent low level of absolute lymphocyte count; <i>Klebsiella pneumoniae</i> detected in sputum	Switched to latamoxef 4 g/day and valganciclovir 1.8 g/day p.o.			
D89	Pleural effusion appeared	Filamentous fungi detected in pleural fluid, Microascus gracilis	Switched antifungal therapy (caspofungin 50 mg/day IV			
	grossly turbid and yellowish	cultured in chest tube and pleural fluid	and posaconazole 0.3 g/day p.o.)			
D99	Relieve respiratory symptoms	BALF mNGS detected Pneumocystis jirovecii, Aspergillus	Adding clindamycin 1.2 g/day IV, thymosin-a-1 4.8			
		fumigate, HCMV and EBV; peripheral blood HCMV DNA	mg/week and intravenous immunoglobulin 400			
		positive; BALF GM test positive	mg/kg/week			
D119	Remove chest tube	Chest tube, pleural fluid and sputum culture were negative	Switched antifungal therapy (terbinafine 250 mg/day p.o. and posaconazole 0.3 g/day p.o. for 4 weeks)			
D133	Outpatient	HCMV DNA negative, high level of CRP and persistent low level of absolute lymphocyte count relieved	Regular follow-up visits			

Abbreviations: D day, CRP C-reactive protein, SAA Serum amyloid A, IV intravenous, p.o per os, CT computed tomographic, BALF bronchoalveolar lavage fluid, mNGS metagenomics next generation sequencing, HCMV human cytomegalovirus, EBV Epstein-Barr virus, GM galactomannan

TABLE 2 Comparison of abnormal biochemical and immunological indicators before and after the administration of immunomodulatory regimens

	Peripheral blood				Pleural effusion									
Time	CD3+T	CD4+T	CD3+PD-1+	CD4+PD-1+	hsCRP	IL-6	CD3+T	CD4+T	CD3+PD-1+	CD4+PD-1+	IL-6	IL-1β	LDH	ADA
	(×10 ⁶ /L)	(×10 ⁶ /L)	(%)	(%)	(mg/L)	(pg/mL)	(n)	(n)	(%)	(%)	(pg/mL)	(pg/m L)	(U/L)	(U/L)
D99	484.7	277	82.4	86.6	130	76.91	737	355	78.3	75.8	>5000	389	1207	22.4
D112	778.8	481.5	28.4	14.2	7.0	36.02	4866	2818	61.7	56.1	510	73.6	192	2.5

Refer ence	Diagnos is year/ nation	Age/g ender	Underlying disease	Transplant type	Systemic antifungal agents before infection	Involved sites	Infection species	Treatment	Outcome		
19	2005/ Belgium	63/M	COPD	SOT (single-lung)	AMB	Heart, thyroid gland, stomach, kidneys, lungs	S. acremonium	VOR/CAS	Expired (1 day)		
20	2007/ India	27/M	AIDS		None	Pleural fluid	S. brumptii		Expired cardiovascular dysfunctions (14 days)		
21	2009/ France	36/M	CF/RF/DM	SOT (heart and lungs)	FCZ	Pleural fluid, intrapericardial fluid, blood clots, bronchial secretions	M. gracilis (M. cirrosus)	VOR/CAS	Expired <u>multiorgan</u> failure (9 days)		
22	2014/ USA	56/M	IPF/DM	SOT (lungs)	ITC	Pulmonary pleura, pleural fluid, skin, ribs, sternum	S. brumptii	MIC/VOR/Am B/TER	Expired Sepsis (48 days)		
23	2020/ USA	65/M	IPF/PH/DM/ HTN/CAD/ HLD	SOT (lungs)	AmB/VOR	Lung, pleura, heart, brain, potential eyes	M. gracilis	AmB/MIC/ISO/ TER	Expired (18 days)		
This case	2023/ China	>65/M	NS/ILD/DM		VOR	Pleural fluid	M. gracilis	CAS/POS/TEB	Cured		

TABLE 3 Demographic features of reported cases with indicated pleural infection by Scopulariopsis/Microascus species

Abbreviations: M, male; COPD, chronic obstructive pulmonary disease; SOT, solid organ transplant; AmB, amphotericin; VOR, voriconazole; CAS, caspofungin; AIDS, acquired immune deficiency syndrome; CF, cystic fibrosis; RF, renal failure; DM, diabetes mellitus; FCZ, fluconazole; IPF, idiopathic pulmonary fibrosis; ITC, itraconazole; MIC, micafungin; TER, terbinafine; PII, pulmonary hypertension; IITN, hypertension; CAD, coronary artery disease; HLD, hyperlipidaemia; ISO, isavuconazole; NS, nephrotic syndrome; ILD, interstitial lung disease; POS, posaconazole.